Sapience Therapeutics, Inc.

Each year, on the third Wednesday of July, the National Brain Tumor Society sponsors #GBMday to recognize the impact of this devastating disease and highlight the national need to advance research, raise awareness, and take action to ultimately cure #glioblastoma. At Sapience Therapeutics, Inc., our Phase 2 study of ST101 is being tested in three cohorts of patients with recurrent and newly diagnosed GBM. We are committed to advancing therapies for patients with this complex, treatment-resistant, and deadliest form of #braincancer. Learn more about GBM here: https://braintumor.org/   #Biotechnology #Oncology

We are pleased to announce that patient enrollment is complete in the Phase 1 portion of our ST316 Phase 1-2 clinical study! Recruitment of the Phase 2 expansion portion will begin in the coming weeks.   ST316 selectively targets the WNT/β-catenin signaling pathway in tumor cells but not in normal cells, reducing the toxicity related to inhibition of this pathway. The WNT/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in Phase 2. We are incredibly proud of the execution by our clinical team in achieving this milestone according to planned timelines. We send heartfelt thanks for the contribution of all participants in this study and the support of our clinical collaborators at each site. #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

We are pleased to announce that patient enrollment is complete in the Phase 1 portion of our ST316 Phase 1-2 clinical study! Recruitment of the Phase 2 expansion portion will begin in the coming weeks.   ST316 selectively targets the WNT/β-catenin signaling pathway in tumor cells but not in normal cells, reducing the toxicity related to inhibition of this pathway. The WNT/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in Phase 2. We are incredibly proud of the execution by our clinical team in achieving this milestone according to planned timelines. We send heartfelt thanks for the contribution of all participants in this study and the support of our clinical collaborators at each site. #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

#ASCO24 is a wrap! Thank you to the meeting organizers for recognizing Sapience's exciting science and providing a broad platform to share our ST101 clinical results in GBM. We enjoyed interacting with industry colleagues, clinical investigators, and patient groups, and it was an honor for our data to be accepted as an oral presentation. #ASCO24 #biotech #GBM

Here is a full recap from our Phase 2 ST101 results in GBM at #ASCO24 presented by Dr. Fabio Iwamoto, MD. Click below for the recap: https://lnkd.in/g-tVWaEr   Click here to access the ASCO slides: https://lnkd.in/gHiPgBm5 #ASCO24 #oncology #GBM

The results demonstrated with ST101 in this GBM study are very encouraging, given the poor prognosis associated with this brain cancer. With the data presented at #ASCO24 today, we believe that ST101 has the potential to be a well-tolerated treatment option for patients, and we look forward to its continued development in combination Phase 2 studies. #ASCO2024 #oncology #GBM

Today at #ASCO2024: Our positive Phase 2 clinical and biomarker results with ST101 in GBM were presented during an oral presentation by Dr. Fabio M. Iwamoto, MD, Principal Investigator of the ST101-101 clinical study. The Phase 2 data demonstrates durable responses with ST101 across 3 cohorts of patients with recurrent and newly diagnosed GBM, and supports its continued clinical development as a backbone treatment in combination with standard-of-care and immune-oncology agents. Learn more about these promising results here: https://lnkd.in/g_V2RPzv #ASCO24 #oncology #GBM

Did you know? More than any other cancer, brain tumors can have lasting and life-altering physical, cognitive, and psychological impacts. That's why we're dedicated to advancing therapies for patients facing challenging brain tumors. Join us in raising awareness by participating in #GoGrayinMay and help shed light on this debilitating disease. Learn more here: https://lnkd.in/g9tztgw8 #Biotechnology #Oncology #Glioblastoma #GBM #BTAM #GrayMay

Dr. Fabio Iwamoto, presenting author at #ASCO24, will give an oral presentation on ST101 in GBM on June 1, 2024. We invite you to attend this scientific session to learn more.    More details can be found here: https://lnkd.in/gKV2npZt   #ASCO24 #Oncology #Glioblastoma #GBM

Attending #ASCO24? The Sapience team is excited to share that we will present new clinical and biomarker data from our ST101 Phase 2 study in glioblastoma during an oral presentation at #ASCO24.   Learn more here: https://lnkd.in/gcX-zh-d   #ASCO24 #Oncology #Glioblastoma #GBM Abi Vainstein-Haras